BMJ  1992;305:913-920 (17 October), doi:10.1136/bmj.305.6859.913

Low molecular weight heparin in prevention of perioperative thrombosis.

Unité de Pharmacologie Clinique, Lyons, France.

OBJECTIVE--To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. DESIGN--Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. SUBJECTS--Patients who had had general or orthopaedic surgery. INTERVENTION--Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. MAIN OUTCOME MEASURES--Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. RESULTS--The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62). CONCLUSIONS--Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Low molecular weight heparin.

P. A. Routledge and R. R. West
BMJ 1992 305: 906. [PDF]

This article has been cited by other articles:

• Hull, R. D., Yusen, R. D., Bergqvist, D. (2009). State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis. CLIN APPL THROMB HEMOST 15: 377-388 [Abstract]  
• Eikelboom, J. W., Karthikeyan, G., Fagel, N., Hirsh, J. (2009). American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ: What Are the Implications for Clinicians and Patients?. Chest 135: 513-520 [Abstract] [Full text]  
• Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., Colwell, C. W. (2008). Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S-453S [Abstract] [Full text]  
• Parry, M., Wylde, V., Blom, A. W. (2008). Ninety-day mortality after elective total hip replacement: 1549 PATIENTS USING ASPIRIN AS A THROMBOPROPHYLACTIC AGENT. J Bone Joint Surg Br 90-B: 306-307 [Abstract] [Full text]  
• Warwick, D., Friedman, R. J., Agnelli, G., Gil-Garay, E., Johnson, K., FitzGerald, G., Turibio, F. M. (2007). Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: FINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY. J Bone Joint Surg Br 89-B: 799-807 [Abstract] [Full text]  
• Thabut, G., Estellat, C., Boutron, I., Samama, C. M., Ravaud, P. (2006). Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism. Eur Heart J 27: 227-236 [Abstract] [Full text]  
• Larson, B. J. G., Zumberg, M. S., Kitchens, C. S. (2005). A Feasibility Study of Continuing Dose-Reduced Warfarin for Invasive Procedures in Patients With High Thromboembolic Risk. Chest 127: 922-927 [Abstract] [Full text]  
• Pineo, G. F., Hull, R. D. (2005). Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly. CLIN APPL THROMB HEMOST 11: 15-23 [Abstract]  
• Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., Ray, J. G. (2004). Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S-400S [Abstract] [Full text]  
• Turpie, A. G.G., Bauer, K. A., Eriksson, B. I., Lassen, M. R. (2004). Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points. Chest 126: 501-508 [Abstract] [Full text]  
• Bombeli, T., Spahn, D. R. (2004). Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesth 93: 275-287 [Abstract] [Full text]  
• Wenzl, M. E., Hasse, W., Seide, K., Wolter, D. (2004). Prevention of Thromboembolism with Low-Molecular-Weight Heparin in Orthopedic Surgery: A 5-Year Experience. CLIN APPL THROMB HEMOST 10: 1-4 [Abstract]  
• Turpie, A. G. G., Eriksson, B. I., Bauer, K. A., Lassen, M. R. (2003). New Pentasaccharides for the Prophylaxis of Venous Thromboembolism: Clinical Studies. Chest 124 : 371S-378S [Abstract] [Full text]  
• Backe, S. K., Lyons, G. R. (2002). High-dose tinzaparin in pregnancy and the need for urgent delivery. Br J Anaesth 89: 331-334 [Abstract] [Full text]  
• Pham, B., Platt, R., McAuley, L., Klassen, T. P., Moher, D. (2001). Is There a "Best" Way to Detect and Minimize Publication Bias?: An Empirical Evaluation. Eval Health Prof 24: 109-125 [Abstract]  
• The Frax.I.S. Study Group, (1999). Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 20: 1553-1562 [Abstract]  
• Juni, P., Witschi, A., Bloch, R., Egger, M. (1999). The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis. JAMA 282: 1054-1060 [Abstract] [Full text]  
• Feuer, D. J, Higgins, J. P T (1999). Meta-analysis. Palliat Med 13: 433-437  
• (1998). Low molecular weight heparins for venous thromboembolism. DTB 36: 25-29 [Abstract] [Full text]  
• Leclerc, J.R. (1997). State-of-the-Art Review: Low-Molecular Weight Heparin Prophylaxis in Surgical Patients. CLIN APPL THROMB HEMOST 3: 153-156  
• Cappelleri, J. C., loannidis, J. P. A., Schmid, C. H., de Ferranti, S. D., Aubert, M., Chalmers, T. C., Lau, J. (1996). Large Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?. JAMA 276: 1332-1338 [Abstract]  
• Sarasin, F. P., Bounameaux, H. (1996). Antithrombotic Strategy After Total Hip Replacement: A Cost-effectiveness Analysis Comparing Prolonged Oral Anticoagulants With Screening for Deep Vein Thrombosis. Arch Intern Med 156: 1661-1668 [Abstract]  
• Prandoni, P., Goldhaber, S. Z., Piccioli, A., Girolami, A. (1996). State-of-the-Art Review : Prevention of Venous Thromboembolism in Major Orthopedic Surgery. CLIN APPL THROMB HEMOST 2: 153-157 [Abstract]  
• Sarasin, F. P., Bounameaux, H. (1996). Cost-effectiveness of Prophylactic Anticoagulation Prolonged After Hospital Discharge Following General Surgery. Arch Surg 131: 694-697 [Abstract]  
• Kearon, C., Hirsh, J. (1995). Starting Prophylaxis for Venous Thromboembolism Postoperatively. Arch Intern Med 155: 366-372 [Abstract]  
• Potyk, D. K. (1994). Meta-analysis Pitfalls: Deep Venous Thrombosis in Patients Undergoing Elective Hip Surgery. Arch Intern Med 154: 1295-1296 [Abstract]  

Online poll

Find out more here>> and here>>